Absci is trading 6.1% down at $10.83 on October 6, 2026, with no verified company-specific announcement identified to explain the decline.
- Absci’s latest identified company news was its September 24 update on planned Phase 2 STORYLINE trial details, which predates this move.
- Supplied sector context reports biotech weakness, but the broader market is higher; neither establishes a clear cause.
- An October 6 article headline notes the stock is down but provides no explanation.